Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AEM 28

Drug Profile

AEM 28

Alternative Names: AEM-28; Apolipoprotein E mimetic

Latest Information Update: 14 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Alabama at Birmingham
  • Developer LipimetiX Development
  • Class Antihyperlipidaemics; Apolipoprotein therapeutics; Peptides
  • Mechanism of Action Apolipoprotein B modulators; Apolipoprotein E agonists; Cholesterol modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type IIa
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia; Hyperlipoproteinaemia type IIa

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 May 2018 AEM 28 licensed to Anji Pharma in China, Taiwan and Hong Kong
  • 26 Aug 2016 AEM 28 is available for licensing as of 29 Jul 2016. http://www.lipimetix.com/businessmodel.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top